公司资料
CVRx 股价、新闻与催化剂
- 股票代码:
- CVRX
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- United States
股票表现
2.75 USD (-10.71%)
收盘价
最后更新: 2026年8月17日
144M USD
市值
股价为何变动
As of Aug 17, 2026, CVRX closed down 10.7% at $2.75. No new same-company headline was identified in the current news window.
公司概览
Cardiovascular Neuromodulation
CVRx is a commercial-stage medical-device company focused on neuromodulation therapies for cardiovascular disease. Its technology electrically activates the body's baroreflex to influence autonomic pathways involved in heart-failure progression.
Barostim Platform
Barostim is the company's implantable therapy for patients with heart failure who remain symptomatic despite guideline-directed medical management. The system is placed by trained physicians and supported through a specialized implanting-center network. CVRx is conducting BENEFIT-HF, a randomized controlled study designed to evaluate Barostim's effect on mortality and heart-failure decompensation in an expanded patient population. The trial complements the company's commercial evidence-generation strategy.
未来催化剂
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。